Agena Bioscience VeriDose CYP2D6 CNV Panel

Nov 05, 2019

Agena Bioscience has launched the VeriDose CYP2D6 CNV panel to provide PGx testing programs with a more accurate and efficient way to analyze CYP2D6 copy number. The research-use-only panel quantifies CYP2D6 copy number even in the presence of CYP2D6/CYP2D7 hybrid alleles, which cannot be detected by commonly used PGx technologies, the company said. The panel can also be run alongside Agena's PGX genotyping panels.

Breaking News

Blood-Based 'Omics Signatures Reflect 'Biological' BMI, Metabolic Health
Oxford Nanopore Technologies, 4bases Collaborate to Develop Rapid BRCA Sequencing Test
Illumina Pushes Back Against Icahn's Proposed Board Nominees
Top Five Articles on GenomeWeb Last Week: Icahn and Illumina, High-Accuracy Sequencing, ACMG, More
Genetic Causes of Three Rare Diseases Identified From UK 100K Genomes Data by Mount Sinai-led Team

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.